Epigenetic changes in FCM, such as increased HIST1H2BN, CENPA, HIST1H1A and HIST1H2AK, may thus be useful for distinguishing FCM from HCM and DCM and may also be a useful therapeutic target for patients with heart failure arising from FCM. This evidence concerns the gene H2BC15 and heart failure.